Asparaginase is an important component of effective treatment strategies for adolescent and young adult patients with acute lymphoblastic leukaemia, but its associated adverse events must be effectively managed. To discuss this, we welcome Dr Dieter Hoelzer, Director of Internal Medicine and ALL specialist at the University of Frankfurt in Germany.

Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.

References:

Aldoss I, Douer D. Blood (2020) 135 (13): 987–995.

Koprivnikar J, et al. Onco Targets Ther. 2017; 10: 1413–1422.

Kamal N, et al. Hepatol Int. 2019; 13(5): 641–648. 

Hijiya N, Van der Sluis I. Leuk Lymphoma. 2016; 57(4): 748–757. 

This independent educational activity is supported by an educational grant from Servier Pharmaceuticals LLC and Takeda. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Servier and Takeda have had no influence on the content of this education.